YD Bio Limited Ordinary Shares (YDES) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

39/ 100

GoAI Score

Sell

Trim exposure — unfavorable risk-reward

Valuation

60

Fair Value

Sentiment

49

Mixed

Risk

66

High Risk

Momentum

19

Strong Down

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

Industry: Biotechnology
Sector: Healthcare
Headquarters: TW
CEO: Ethan Shen
Listed since: Aug 29, 2025
Employees: 15

Market position

Day range

Current $3.54

$3.30$3.88

52-week range

Current $3.54

$1.70$25.00

Open: $3.67
Previous close: $3.67
Volume: 687.09K; 5.5× average
Average volume: 125K; Average daily volume
Market cap: 250.74M USD
Beta: -0.12; Market reference 1
50-day average: $2.8513; +24.15% above average
200-day average: $6.7775; -47.77% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 807.31M USD
P/E (TTM): -2.17×
P/B (TTM): -4.23×
P/S (TTM): 0×
EV / EBITDA: -99.63×
Earnings yield: -1.02%
Free cash flow yield: -0.99%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 291.05%
Return on assets: -60.32%
Return on invested capital: -43.41%

Financial health

Debt / equity: -0×
Current ratio: 5.88×
Altman Z-score: 8.55
Piotroski F-score: 3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

596.82K USD+16.94%

Operating income

−5.27M USD-260.60%

Net income

−8.31M USD-488.80%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	596.82K USD	510.36K USD	350.13K USD	—	—
Cost of goods sold	638.97K USD	355K USD	196.69K USD	—	—
Gross profit	−42.15K USD	155.36K USD	153.45K USD	—	—
Research and development	1.6M USD	491.35K USD	—	—	—
Selling, general, and administrative	3.63M USD	1.13M USD	160.56K USD	2.32M USD	1.72M USD
Operating expenses	5.23M USD	1.62M USD	163.29K USD	2.32M USD	1.72M USD
Interest income	80.16K USD	11.81K USD	290 USD	813 USD	764 USD
Interest expense	—	772 USD	2.14K USD	—	—
Depreciation and amortization	209.56K USD	104.74K USD	2.45K USD	—	—
Operating income	−5.27M USD	−1.46M USD	−9.85K USD	−2.32M USD	−1.72M USD
Net income	−8.31M USD	−1.41M USD	13.56K USD	3.79M USD	8.7M USD

Company facts updated Sep 6, 2026.

Earnings

Latest fiscal-year EPS: -0.12; FY2025
Latest fiscal-year revenue: 596.82K USD; FY2025 · +16.94% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

YDES news

globenewswire.comAug 31, 2026

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic…

Read source

globenewswire.comAug 25, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic…

Read source

defenseworld.netAug 16, 2026

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the…

Read source

globenewswire.comJul 28, 2026

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) --…

Read source

globenewswire.comJul 23, 2026

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic…

Read source

globenewswire.comJul 2, 2026

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic…

Read source

YDES peers

AMGN

Amgen Inc.

$437.23

-1.55%

GILD

Gilead Sciences, Inc.

$151

-0.15%

VRTX

Vertex Pharmaceuticals Incorporated

$546.12

-2.12%

ISRG

Intuitive Surgical, Inc.

$366.7

-0.85%

SNY

Sanofi

$44.24

-0.20%

REGN

Regeneron Pharmaceuticals, Inc.

$827.72

-1.87%

ETFs holding YDES

Funds reporting this stock among their holdings, ordered by reported position size.

ETFMarket valueWeightAUMExpense ratioPrice / 1D

Fidelity Nasdaq Composite Index ETFONEQ83.89K—10.35B USD0.21%$104.46-0.29%

Fidelity Nasdaq Composite Index ETFONEQ

Market value: 83.89K
Weight: —
AUM: 10.35B USD
Expense ratio: 0.21%
Price / 1D: $104.46-0.29%

YD Bio Limited Ordinary Shares

YDES company overview

Company profile

YD Bio Limited Ordinary Shares

YDES company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

Annual EPS trend

Annual revenue trend

YDES news

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YDES peers

ETFs holding YDES

Continue in GoAI

YDES company overview

Company profile

Market position

YDES company overview

Company profile

YDES company overview

Company profile

Market position

YDES company overview

GoAI snapshot

Company profile

Market position

Financials

Financial snapshot

Valuation & yield

Profitability & efficiency

Financial health

Financial statements

Margin trends

Income trends

Earnings

Annual EPS trend

Annual revenue trend

YDES news

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YDES peers

ETFs holding YDES

Continue in GoAI